Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor. The aim of the present study was to evaluate, in an open-label pilot study, the effects and safety of very small doses of aripiprazole on l-dopa-induced dyskinesia of a group of PD patients who did not show a significant clinical benefit by pharmacological treatment with amantadine and mirtazapine. Twelve PD patients with peak-dose LID were enrolled in a period of 1 year. Aripiprazole dosage was of 0.625 mg/day. The ten patients who continued taking aripiprazole displayed a significant decrease in the intensity and frequency of dyskinesias in all parts of the body, particularly in trunk movements (AIMS score T0 = 14.1 ± 3.6 vs. final score 2.4. ± 2.6; P = 0.005). Our study suggests that aripiprazole at very low doses is tolerated and could be efficacy in treating LID.
Durif F, Debilly B, Galitzky M et al (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62:381–388PubMedGoogle Scholar
Fernandez HH, Trischmann ME, Friedman JH (2004) Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminar experience. Clin Neuropharmacol 27:4–5PubMedCrossRefGoogle Scholar
Friedman JH, Berman RM, Goetz CG et al (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov Disord 21:2078–2081PubMedCrossRefGoogle Scholar
Grunder G, Kungel M, Ebrecth M et al (2006) Aripiprazole: pharmacodynamics of dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl 1):S21–S25PubMedCrossRefGoogle Scholar
Meco G, Marini S, Lestingi L et al (1988) Controlled single-blinde crossover study of ritanserin and placebo in induced dyskensia. Current Ther Res 43:262–270Google Scholar